Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination
are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or
RCC) that has advanced or spread to other areas the body.